Company / R&D Expense
Matinas BioPharma Holdings, Inc. R&D Expense History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$11.4M
FY2024
5-year range
$11.4M / $16.7M
FY2020-FY2024
Trend
-31.4%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has fluctuated over the past 10 years, ranging from $4M in FY2016 to $17M in FY2023.
Based on SEC 10-K filings.
$11M in FY2024 with a 5-year CAGR of +11.0%.
Declined from $15M to $11M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -7.8%
- 5-Year CAGR
- +11.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +11.0%, indicating consistent growth.
- In FY2024, r&d expense decreased 31.4% year-over-year.
- Peak r&d expense was recorded in FY2023.
- Lowest r&d expense in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $11.4M | -31.4% |
| FY2023 | $16.7M | +14.4% |
| FY2022 | $14.6M | +0.0% |
| FY2021 | $14.6M | +1.6% |
| FY2020 | $14.4M | +111.6% |
| FY2019 | $6.8M | -24.7% |
| FY2018 | $9.0M | +70.3% |
| FY2017 | $5.3M | +34.1% |
| FY2016 | $3.9M | -25.4% |
| FY2015 | $5.3M | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026